Glycosylated Polypeptide and Drug Composition Containing said Polypeptide
AssigneeGlytech, Inc.
InventorsHirofumi Ochiai, Taiji Shimoda, Kazuhiro Fukae, Masatoshi Maeda, Kazuyuki Ishii, Kenta Yoshida, Katsunari Tezuka, Keisuke Tazuru
Life of this patent
Estimating the term…
Abstract
[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analogue thereof being replaced with a glycosylated amino acid.
Claims10
1-35. (canceled)
A glycosylated polypeptide selected from the group consisting of:
- (A) a SRIF14 consisting of the amino acid sequence of SEQ ID NO:1;
- (B) a polypeptide having one or a few amino acids deleted from, substituted with, or added to SRIF14, SRIF14 consisting of the amino acid sequence of SEQ ID NO:1;
- (C) a SRIF14 analog;
- (D) a polypeptide having 80% or more homology with SRIF14 consisting of the amino acid sequence of SEQ ID NO:
- 1;
- (E) a polypeptide further comprising N amino acids at the N-terminal side of (A)-(D), wherein N is an integer from 1 or more to 20 or less at the N-terminal side of (A)-(D);
- and
- (F) a polypeptide further comprising M amino acids at the C-terminal side of (A)-(D), wherein M is an integer from 1 or more to 6 or less;
- wherein at least one amino acid is substituted with a glycosylated amino acid, and the polypeptide has affinity towards somatostatin receptors.
A method for treating or preventing a somatostatin-related disease, comprising administering to a patient in need thereof an effective amount of a glycosylated polypeptide of claim 1.
Dependencies are inferred from the claim text.